The findings of this study suggest that melanoma patients with BRAF or NRAS mutant tumours have an increased risk compared to patients with BRAF/NRAS wild-type tumours of developing disease recurrence following a tumour-negative SLNB. This evidence concerns the gene BRAF and melanoma.